Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

This study is an open-label, randomized, multicenter phase II/III clinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy in previously untreated participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR atypical mutations. The study comprises two stages: phase II (dose-exploration stage) and phase III (pivotal study stage)

Trial Details

NCT ID
NCT07336732
Phase
PHASE2
Sponsor
Avistone Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Squamous Cell Lung Cancer
Interventions
  • PLB1004
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Age ≥18 years at the time of ICF signing.
  • Histologically or cytologically confirmed, unresectable locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-squamous non-small cell …
  • Confirmed EGFR atypical mutation.
  • No prior systemic therapy for locally advanced or metastatic NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Lung Cancer Trials on Trialify →